Stonepine Capital Management LLC Raises Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Stonepine Capital Management LLC boosted its stake in UroGen Pharma Ltd. (NASDAQ:URGN) by 15.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 324,324 shares of the company’s stock after buying an additional 43,979 shares during the quarter. UroGen Pharma makes up about 2.8% of Stonepine Capital Management LLC’s holdings, making the stock its 13th biggest position. Stonepine Capital Management LLC owned about 1.38% of UroGen Pharma worth $3,454,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of UroGen Pharma by 4.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company’s stock worth $231,000 after acquiring an additional 969 shares during the last quarter. Rhumbline Advisers increased its position in UroGen Pharma by 2.8% during the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock worth $546,000 after purchasing an additional 1,402 shares in the last quarter. MetLife Investment Management LLC raised its stake in UroGen Pharma by 13.6% in the 4th quarter. MetLife Investment Management LLC now owns 22,766 shares of the company’s stock valued at $242,000 after purchasing an additional 2,727 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in UroGen Pharma by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company’s stock valued at $996,000 after purchasing an additional 3,024 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of UroGen Pharma by 24.6% during the 4th quarter. Legal & General Group Plc now owns 19,845 shares of the company’s stock worth $211,000 after purchasing an additional 3,920 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

UroGen Pharma Price Performance

URGN opened at $7.31 on Friday. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The company’s 50-day moving average price is $10.59 and its 200 day moving average price is $10.89. UroGen Pharma Ltd. has a fifty-two week low of $6.46 and a fifty-two week high of $20.70. The firm has a market cap of $337.04 million, a price-to-earnings ratio of -2.32 and a beta of 0.66.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The firm had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. As a group, sell-side analysts expect that UroGen Pharma Ltd. will post -3.12 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Scotiabank started coverage on UroGen Pharma in a research note on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 price target on the stock. LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a research report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 target price for the company. The Goldman Sachs Group cut their price objective on shares of UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating on the stock in a report on Thursday, April 17th. HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of UroGen Pharma in a research report on Tuesday, May 13th. Finally, Guggenheim reaffirmed a “buy” rating on shares of UroGen Pharma in a report on Tuesday, April 29th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, UroGen Pharma presently has a consensus rating of “Buy” and a consensus target price of $32.86.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.